Executive Summary

This meta-analysis critically evaluates the efficacy of metformin as an adjuvant therapy in gynecologic malignancies, specifically focusing on progression-free survival (PFS) and overall survival (OS). Despite its potential antitumor effects suggested by preclinical and epidemiological studies, the findings from randomized controlled trials (RCTs) indicate that metformin does not significantly improve PFS or OS when combined with standard therapies in patients with cervical, endometrial, or ovarian cancers. The analysis underscores the necessity for larger, multicenter trials to explore the therapeutic benefits of metformin, particularly in patients with metabolic abnormalities, and to assess its integration with novel therapeutic strategies.

Context & Background

Gynecologic malignancies, including cervical, endometrial, and ovarian cancers, represent a significant public health challenge, with increasing incidence and mortality rates among women globally. The World Health Organization reported approximately 660,000 new cases of cervical cancer and 350,000 related deaths in 2022, highlighting the urgent need for effective therapeutic interventions. The rising prevalence of these malignancies is particularly concerning in developed regions, where lifestyle factors such as obesity and metabolic syndrome contribute to the increasing incidence of endometrial cancer. Despite advancements in treatment modalities, including surgery, radiotherapy, and chemotherapy, the prognosis for patients with advanced-stage gynecologic cancers remains poor, necessitating the exploration of novel adjuvant therapies to enhance survival outcomes.

Deep Analysis

Metformin, a widely utilized oral hypoglycemic agent, has garnered attention for its potential antitumor properties, particularly in patients with diabetes mellitus (DM). Preclinical studies have elucidated various mechanisms through which metformin may exert its antitumor effects, including the activation of AMP-activated protein kinase (AMPK) and inhibition of the PI3K/AKT/mTOR signaling pathway. These mechanisms contribute to reduced tumor cell proliferation and enhanced apoptosis, suggesting a biological rationale for metformin’s use in conjunction with standard cancer therapies. Epidemiological evidence further supports the hypothesis that metformin may lower cancer risk and improve outcomes in diabetic patients; however, clinical trial results remain inconsistent, particularly in the context of gynecologic malignancies. This meta-analysis synthesizes findings from five RCTs involving 705 patients, revealing that metformin does not significantly improve PFS or OS compared to standard therapies alone. Notably, subgroup analyses indicated no survival benefits for cervical or endometrial cancer patients, while only one study suggested a potential improvement in PFS for ovarian cancer, albeit with limited reliability due to wide confidence intervals.

Recommendations

• Conduct larger, multicenter randomized controlled trials to further investigate the efficacy of metformin in gynecologic malignancies.
• Explore the potential benefits of metformin in patients with metabolic abnormalities and its synergistic effects with novel therapeutic agents.
• Implement standardized protocols for metformin administration in clinical trials to minimize variability in treatment regimens.
• Encourage interdisciplinary collaboration among oncologists, endocrinologists, and researchers to enhance understanding of metformin’s role in cancer therapy.

Conclusion

In conclusion, while metformin presents a promising avenue for adjuvant therapy in gynecologic malignancies, current evidence from randomized controlled trials does not support its efficacy in significantly improving progression-free or overall survival. Future research should focus on elucidating the conditions under which metformin may be beneficial, particularly in the context of metabolic disorders, and integrating it with emerging therapeutic strategies to optimize patient outcomes.